Long‐term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10‐year follow‐up study
Cholinesterase inhibitors slow cognitive decline over a 5-year follow-up period when compared to both memantine treatment and nonuse in patients with dementia with Lewy bodies. Cholinesterase Inhibitors reduce risk of mortality within the initial year, but this effect is not sustained after 1 year in patients with dementia with Lewy bodies.
Authors
- Maria Eriksdotter (ORCID: https://orcid.org/0000-0003-2498-4000)
- Hong Xu (ORCID: https://orcid.org/0000-0002-7266-3431)
- Daniel Ferreira (ORCID: https://orcid.org/0000-0001-9522-4338)
- Annegret Habich (ORCID: https://orcid.org/0000-0002-2267-1206)
- Eric Westman (ORCID: https://orcid.org/0000-0002-3115-2977)
- Londos Elisabet
Institutions
- University of Bern (CH)
- Karolinska University Hospital (SE)
- Lund University (SE)
- University Hospital of Bern (CH)
- Karolinska Institutet (SE)
- Universidad Fernando Pessoa Canarias (ES)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1002/alz.14118
- Citations
- 14
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 5.40
Funders
- Hjärnfonden
- Karolinska Institutet
- Vetenskapsrådet
- Umeå Universitet
- Alzheimerfonden
- Demensfonden
- Center for Innovative Medicine